Skip to main content
. 2019 Jun 26;10:1422. doi: 10.3389/fimmu.2019.01422

Figure 3.

Figure 3

The adjuvant capacity of SLP-8348 is a glycan-mediated process. BALB/c mice were subcutaneously injected with one dose (10 μg/mouse) of SLP-8348 + OVA, oxidized SLP-8348 (SLPOx-8348) + OVA, PBS + OVA (OVA), or PBS (PBS). Cells were labeled with CFSE and stimulated in vitro with OVA (10 μg/ml) for 5 days. Proliferation index of CD4+ T cells in each experimental group was calculated as the ratio between the percentage of CFSE low CD4+ cells and CFSElow CD4+ cells from OVA-treated mice (A). IFN-γ levels in supernatants (B). A representative figure of three independent experiments is shown (±SD, indicated by error bars). Asterisks indicate statistically significant differences by one-way ANOVA with Tukey's post hoc test (*p < 0.05).